EpiVax

EpiVax is an American biotechnology company, founded in 1998 by Anne Searls De Groot. EpiVax holds the exclusive license to the EpiMatrix vaccine design technology.
In 2015, EpiVax collaborated with Ipsen to complete a new approach for producing botulinum neurotoxin and Targeted Secretion Inhibitor therapeutics. EpiVax applied its proprietary T cell epitope modification technology to generate an engineered BoNT sequence.
In 2020, it developed a COVID-19 vaccine, EPV-CoV19, in partnership with the University of Georgia and Immunomic Therapeutics.